Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 millionCash and cash ...
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell ...
Interaksyon on MSN2m
Email signatures are harming the planet and could cost people their lives — it’s time to stop using themThe use of information technology (IT) has significant environmental and social impacts, including human mortality from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback